Summary
- One of Pfizer’s scientific forte is the clinical development of effective therapeutics for dyslipidemia, cardiovascular, and metabolic disorders.
- PF-05221304, the lead investigative drug candidate, is an acetyl-CoA carboxylase inhibitor currently in Phase 2a monotherapy and combination clinical trials in patients with NAFLD or NASH.
- Mechanistically, PF-05221304 is pharmacologically designed to suppress de novo lipogenesis leading to improvement in steatosis in patients with NAFLD or NASH.
- The top-line data readout for the Phase 2a monotherapy NAFLD and NASH trial is expected in late Q2/2019.
- Looking for more? I update all of my investing ideas and strategies to members of Liver Therapy Forum (LTF). Get started today »
Investment Thesis
Pfizer (NYSE:PFE) is a large-cap ($232B) global biopharmaceutical company widely known for the development of the blockbuster cardiovascular drug, Lipitor. Lipitor is perhaps the most recognized statin drug that is used clinically and over the counter to lower bad cholesterol, LDL-C. Pfizer is also a proven pioneer of therapeutics for HIV infection, autoimmune, and gastrointestinal diseases as well as hematological and oncological ailments. Presently, it is clinically assessing the therapeutic effects of small drug molecules targeting the fibrotic liver disease, NASH.
